Suppr超能文献

一种基于无动物源微载体的搅拌培养系统,用于从骨髓和脂肪组织中分离的人间充质干/基质细胞的可扩展扩增。

A xeno-free microcarrier-based stirred culture system for the scalable expansion of human mesenchymal stem/stromal cells isolated from bone marrow and adipose tissue.

作者信息

Carmelo Joana G, Fernandes-Platzgummer Ana, Diogo Maria Margarida, da Silva Cláudia Lobato, Cabral Joaquim M S

机构信息

Department of Bioengineering and IBB - Institute for Bioengineering and Biosciences, Instituto Superior Técnico, Universidade de Lisboa, Lisboa, Portugal.

出版信息

Biotechnol J. 2015 Aug;10(8):1235-47. doi: 10.1002/biot.201400586. Epub 2015 Jul 24.

Abstract

Human mesenchymal stem/stromal cells (MSC) are promising candidates for cell-based therapies and the development of microcarrier-based cultures in scalable bioreactors with well-defined xenogeneic-free components represent important milestones towards the clinical-scale production of these cells. In this work, we optimized our previously developed xeno-free microcarrier-based system for the scalable expansion of human MSC isolated from bone marrow (BM MSC) and adipose-derived stem/stromal cells (ASC). By adapting the agitation/feeding protocol at the initial cell seeding/cultivation stage in spinner flasks, we were able to maximize cell expansion rate and final cell yield. Maximal cell densities of 3.6 × 10(5) and 1.9 × 10(5) cells/mL were obtained for BM MSC (0.60 ± 0.04 day(-1) ) and ASC (0.9 ± 0.1 day(-1) ) cultures, upon seven and eight days of cultivation, respectively. Ready-to-use microcarriers Synthemax® II and Enhanced Attachment® supported identical expansion performance of BM MSC, turning those effective alternatives to the pre-coated plastic microcarriers used in our xeno-free scalable culture system. Importantly, expanded MSC maintained their immunophenotype and multilineage differentiation potential. Moreover, secretome analysis suggested a priming effect of stirred culture conditions on cytokine production by MSC. This culture system yielded considerable final cell densities that can be scaled-up to controlled large-scale bioreactors allowing a more efficient, safe and cost-effective MSC production for clinical settings.

摘要

人间充质干/基质细胞(MSC)是基于细胞疗法的有前景的候选者,并且在具有明确无外源成分的可扩展生物反应器中开发基于微载体的培养物是这些细胞临床规模生产的重要里程碑。在这项工作中,我们优化了我们之前开发的基于无外源微载体的系统,用于从骨髓(BM MSC)和脂肪来源的干/基质细胞(ASC)中分离的人MSC的可扩展扩增。通过在转瓶中初始细胞接种/培养阶段调整搅拌/补料方案,我们能够最大化细胞扩增率和最终细胞产量。在培养7天和8天后,BM MSC(0.60±0.04天⁻¹)和ASC(0.9±0.1天⁻¹)培养物分别获得了3.6×10⁵和1.9×10⁵个细胞/mL的最大细胞密度。即用型微载体Synthemax® II和Enhanced Attachment®支持BM MSC的相同扩增性能,成为我们无外源可扩展培养系统中使用的预包被塑料微载体的有效替代品。重要的是,扩增的MSC保持其免疫表型和多向分化潜能。此外,分泌组分析表明搅拌培养条件对MSC细胞因子产生有启动作用。这种培养系统产生了相当可观的最终细胞密度,可以扩大到可控的大规模生物反应器,从而为临床环境生产更高效、安全和经济有效的MSC。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验